Targeting Cancer PCI and Saporin conjugates

Enhanced Targeting of Triple-Negative Breast Carcinoma and Malignant Melanoma by Photochemical Internalization of CSPG4-Targeting Immunotoxins. Eng MS, Kaur J, Prasmickaite L, Engesaeter BO, Weyergang A, Skarpen E, Berg K, Rosenblum MG, Maelandsmo GM, Hogset A, Ferrone S, & Selbo PK. (2018). Photochemical & Photobiological Sciences 17(5):539-551.

Conclusion: The combination of the drug delivery technology PCI and CSPG4-targeting immunotoxins is an efficient, specific and light-controlled strategy for the elimination of aggressive cells of TNBC and malignant melanoma origin. This study lays the foundation for further preclinical evaluation of PCI in combination with CSPG4-targeting.

Dose: To obtain the immunotoxin 225.28-saporin, Streptavidin-Saporin (Cat. #IT-27; Streptavidin-ZAP), with an average of 2.5 molecules of saporin per molecule of streptavidin, was combined with
biotinylated 225.28, a CSPG4-specific mouse mAb, IgG2a.